Goldman Sachs
CPRX

Goldman Sachs’s Catalyst Pharmaceutical CPRX Stock Holding History

Goldman Sachs’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Buy
+50,000
New +$1.19M ﹤0.01% 4935

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs's CPRX Position: Q1 2026 in Review

Goldman Sachs increased its Catalyst Pharmaceutical (CPRX) stake by 0.53% in Q1 2026, buying an estimated $124K and bringing the position to 984,734 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

Goldman Sachs first reported a position in CPRX in Q3 2014 and has held it in 46 quarters since. The position peaked at $76M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Goldman Sachs held 984,734 shares of Catalyst Pharmaceutical worth $24.4M as of Q1 2026.
  • Goldman Sachs bought 5,191 Catalyst Pharmaceutical shares in Q1 2026, an estimated $124K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2249 holding.
  • Goldman Sachs first reported a position in Catalyst Pharmaceutical in Q3 2014 and has held it in 46 quarters since.
  • Goldman Sachs's Catalyst Pharmaceutical position peaked at $76M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.